Oncology · Module 4 of 6

Topoisomerase Inhibitors and Antitumor Antibiotics

Camptothecins, anthracyclines, etoposide, bleomycin, and actinomycin D

Topoisomerase inhibitors are divided by target enzyme: camptothecins (irinotecan, topotecan) trap topoisomerase I cleavable complexes, generating lethal double-strand breaks only at replication forks — making them S-phase specific with no secondary leukemia risk. Anthracyclines and etoposide trap topoisomerase II complexes in any cell cycle phase and carry a well-characterized risk of secondary AML driven by KMT2A rearrangements (latency 1–3 years).
Irinotecan is a prodrug converted by carboxylesterase to SN-38, its active metabolite. SN-38 is glucuronidated by UGT1A1 for elimination; patients homozygous for the UGT1A1*28 allele have reduced UGT1A1 activity, impaired SN-38 clearance, and significantly increased risk of severe neutropenia and diarrhea — dose reduction should be considered. Irinotecan causes two mechanistically distinct diarrheas: early (cholinergic, within 24 hours, treat with atropine) and late (SN-38 mucosal toxicity, after 24 hours, treat with high-dose loperamide).
Doxorubicin kills tumor cells through three simultaneous mechanisms — DNA intercalation with topoisomerase II-alpha inhibition, reactive oxygen species generation via semiquinone radical cycling, and cardiolipin binding in the mitochondrial inner membrane. The cardiac isoform topoisomerase II-beta mediates cardiomyocyte DNA damage; cumulative dose limits are 450–550 mg/m² for doxorubicin and ~900 mg/m² for epirubicin. Dexrazoxane (10:1 ratio with doxorubicin) is the only approved cardioprotectant and works by chelating iron, reducing ROS generation.
Bleomycin causes DNA strand scission via iron chelation and ROS generation. It is G2/M phase specific. Pulmonary toxicity — the critical adverse effect — occurs in approximately 10% of patients at BEP doses and risk rises significantly above 400 units cumulative lifetime dose. Serial DLCO monitoring is required. Low bleomycin hydrolase activity in lung tissue explains the organ-specific vulnerability.
Any prior bleomycin exposure creates a permanent anesthesia hazard: high inspired oxygen concentrations (high FiO₂) during or after general anesthesia can precipitate acute respiratory distress syndrome. There is no established safe interval after treatment. Bleomycin history must be prominently documented and communicated to the anesthesia team before every procedure, elective or emergency.

ARDS = acute respiratory distress syndrome · BEACOPP = bleomycin + etoposide + doxorubicin + cyclophosphamide + vincristine + procarbazine + prednisone · BEP = bleomycin + etoposide + cisplatin · DLCO = diffusing capacity for carbon monoxide · DSB = double-strand break · FiO₂ = fraction of inspired oxygen · GCT = germ cell tumor · KMT2A = lysine methyltransferase 2A (formerly MLL) · LVEF = left ventricular ejection fraction · ROS = reactive oxygen species · SCLC = small cell lung cancer · UGT1A1 = UDP-glucuronosyltransferase 1A1

Topoisomerase I vs II Inhibitors — Mechanism and Safety Profile

Topoisomerase I Inhibitors

Camptothecins: Irinotecan & Topotecan

Trap topo I cleavable complex → single-strand nick becomes lethal DSB only at replication fork → S-phase specific
No secondary leukemia risk; no cumulative cardiotoxicity
Irinotecan: prodrug → SN-38 (active) via hepatic and intestinal carboxylesterase; SN-38 is 100–1,000× more potent than irinotecan
UGT1A1*28 homozygotes: impaired SN-38 glucuronidation → prolonged exposure → severe neutropenia and diarrhea; consider dose reduction before first cycle
Early diarrhea (<24 h): cholinergic mechanism → treat with atropine; late diarrhea (>24 h): SN-38 mucosal toxicity → treat with high-dose loperamide
Topotecan: SCLC, ovarian cancer; dose-limiting toxicity is myelosuppression

Topoisomerase II Inhibitors

Anthracyclines & Etoposide

Trap topo II cleavable complex → DSBs in any cell cycle phase (cycle-nonspecific for DNA damage)
Anthracyclines: cumulative cardiomyopathy via topo II-beta DSBs in cardiomyocytes + ROS generation; doxorubicin limit 450–550 mg/m²; epirubicin limit ~900 mg/m²
Dexrazoxane: only approved cardioprotectant; give at 10:1 ratio with doxorubicin; iron chelation reduces cardiac ROS
Etoposide: secondary AML via KMT2A rearrangement; latency 1–3 years; incidence ~1–2% in BEP, ~3–5% in BEACOPP
Monitor LVEF before and during anthracycline therapy; baseline echo or MUGA required

Doxorubicin — Three Simultaneous Mechanisms

Mechanism	Detail	Clinical Consequence
DNA intercalation + topo II-alpha inhibition	Planar anthracycline chromophore inserts between DNA base pairs; stabilizes topo II cleavable complex → persistent DSBs in tumor cells	Primary antitumor activity; topo II-beta DSBs in cardiomyocytes contribute to cardiomyopathy
ROS generation via semiquinone radical	One-electron reduction of quinone → semiquinone radical → reacts with O₂ → superoxide → hydroxyl radical (Fenton chemistry with iron)	DNA, protein, and lipid oxidative damage; cardiomyocytes especially vulnerable due to low catalase activity
Cardiolipin binding	Doxorubicin intercalates into cardiolipin, the signature phospholipid of the mitochondrial inner membrane	Disrupts electron transport chain integrity; triggers mitochondrial apoptosis pathway in cardiomyocytes

Antitumor Antibiotics

Antitumor Antibiotic

Bleomycin — DNA Strand Scission & Pulmonary Risk

Mechanism: bleomycin chelates Fe²⁺ → binds DNA → ROS generation → direct single- and double-strand cleavage; G2/M phase specific
Low bleomycin hydrolase activity in lung (and skin) → drug accumulates → organ-specific toxicity
Pulmonary toxicity in ~10% at BEP doses; risk rises sharply above 400 units cumulative lifetime dose
Monitor with serial DLCO measurements; decline >10–15% from baseline warrants dose reduction or discontinuation
Indications: BEP (testicular germ cell tumors), ABVD (Hodgkin lymphoma)

Antitumor Antibiotic

Actinomycin D (Dactinomycin)

Intercalates at GC base pairs → physically blocks RNA polymerase movement → inhibits transcription of all RNA species (mRNA, rRNA, tRNA)
Potent radiation sensitizer: blocks transcription of DNA repair enzymes, compounding radiation-induced damage
Indications: Wilms tumor, gestational trophoblastic disease, Ewing sarcoma, rhabdomyosarcoma
Dose-limiting toxicities: myelosuppression, mucositis, and radiation recall dermatitis
Extreme vesicant: extravasation causes severe tissue necrosis — central venous access and strict extravasation protocols required

Clinical Safety Rule

Bleomycin and Anesthesia — No Safe Oxygen Threshold

Any patient with prior bleomycin exposure requires inspired oxygen fraction to be kept at the minimum consistent with safe oxygenation (SpO₂ target 93–95%) during and after general anesthesia. High FiO₂ in bleomycin-exposed lung tissue generates an exaggerated ROS response that can precipitate acute respiratory distress syndrome — a life-threatening and often irreversible complication.

There is no established safe interval after bleomycin treatment beyond which normal FiO₂ can be resumed. Bleomycin history must be documented prominently in the patient chart and communicated explicitly to the anesthesia team before every elective or emergency procedure, regardless of how long ago treatment occurred.

References

Author / Source	Title	Publication
Katzung BG (ed)	Basic & Clinical Pharmacology, 15th ed.	McGraw-Hill, 2021
Brunton LL, Knollmann BC (eds)	Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed.	McGraw-Hill, 2023
Pommier Y	Topoisomerase I inhibitors: camptothecins and beyond	Nat Rev Cancer. 2006;6(10):789–802
Pommier Y, Sun Y, Huang SN, Nitiss JL	Roles of eukaryotic topoisomerases in transcription, replication and genomic stability	Nat Rev Mol Cell Biol. 2016;17(11):703–721
Pizzolato JF, Saltz LB	The camptothecins	Lancet. 2003;361(9376):2235–2242
Iyer L, Das S, Janisch L, et al	UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity	Pharmacogenomics J. 2002;2(1):43–47
Hande KR	Etoposide: four decades of development of a topoisomerase II inhibitor	Eur J Cancer. 1998;34(10):1514–1521
Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L	Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity	Pharmacol Rev. 2004;56(2):185–229
Weiss RB	The anthracyclines: will we ever find a better doxorubicin?	Semin Oncol. 1992;19(6):670–686
Swain SM, Whaley FS, Ewer MS	Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials	Cancer. 2003;97(11):2869–2879
Chen J, Stubbe J	Bleomycins: towards better therapeutics	Nat Rev Cancer. 2005;5(2):102–112
de Wit R, Roberts JT, Wilkinson PM, et al	Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer	J Clin Oncol. 2001;19(6):1629–1640
Lipshultz SE, Lipsitz SR, Mone SM, et al	Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer	N Engl J Med. 1995;332(26):1738–1743
Swain SM, Whaley FS, Gerber MC, et al	Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer: a randomized trial	J Clin Oncol. 1997;15(4):1318–1332